희귀질환 유전자 검사 시장 규모, 점유율, 동향 분석 보고서 : 질환별, 기술별, 전문 분야별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Rare Disease Genetic Testing Market Summary

The global rare disease genetic testing market size was estimated at USD 1,293.15 million in 2025 and is projected to reach USD 3,883.76 million by 2033, growing at a CAGR of 14.87% from 2026 to 2033. The market is driven by advancements in next-generation sequencing (NGS), increased awareness of rare genetic disorders, and rising demand for personalized medicine.

In addition, strict regulations from various government bodies requiring alcohol and substance testing for safety reasons, along with increased initiatives to monitor and address substance abuse, are anticipated to further enhance market growth.

The expansion and maturation of rare disease patient registries have emerged as a critical driver for the growth of the rare disease genetic testing market. These registries systematically aggregate phenotypic data, longitudinal clinical histories, genomic sequencing results, and patient-reported outcomes, thereby creating a centralized, structured data ecosystem. By transforming fragmented clinical information into cohesive datasets, registries enable clinicians and diagnostic laboratories to identify genotype-phenotype correlations more effectively, refine variant interpretation, and improve diagnostic accuracy.

This development is particularly significant given the scale and complexity of rare diseases, which affect over 300 million individuals globally, with approximately 25 to 30 million cases in the United States alone. Despite advances in diagnostics, the average diagnostic journey still exceeds six years, with only around 40% of patients receiving a confirmed diagnosis. Moreover, nearly 80% of rare diseases are genetic in origin, and about half of diagnosed cases occur in children, highlighting the urgent need for efficient and accurate genetic testing solutions.

The continuous decline in genome sequencing costs represents another major driver accelerating the growth of the rare disease genetic testing market. Over the past two decades, sequencing has evolved from an extremely expensive and time-intensive process-costing nearly USD 3 billion per genome in the early 2000s-to a highly accessible technology, with costs projected to reach approximately USD 200 per genome by 2025. This dramatic reduction has been driven by advances in next-generation sequencing technologies and by increasing competition among key industry players, such as Illumina and Ultima Genomics.

Lower sequencing costs have far-reaching implications beyond affordability. They enable laboratories to scale up testing volumes while simultaneously investing in improvements across the diagnostic workflow. On the upstream side, laboratories are enhancing sample processing capabilities through faster extraction techniques and streamlined workflows. Downstream, there is increased investment in advanced bioinformatics, including automated variant calling, continuous reanalysis pipelines, and integrated clinical decision support systems.

Global Rare Disease Genetic Testing Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global rare disease genetic testing market report on the basis of disease, specialty, technology, end use and region:

• Disease Outlook (Revenue, USD Million, 2021 - 2033)
• Neurological Disorders
• Immunological Disorders
• Hematology Diseases
• Endocrine & Metabolism Diseases
• Cancer
• Musculoskeletal Disorders
• Cardiovascular Disorders
• Dermatology Diseases
• Other Rare Diseases
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Next Generation Sequencing
  • Whole Exome Sequencing
  • Whole Genome Sequencing
• Array Technology
• PCR-based Testing
• FISH
• Sanger Sequencing
• Karyotyping
• Specialty Outlook (Revenue, USD Million, 2021 - 2033)
• Molecular Genetic Tests
• Chromosomal Genetic Tests
• Biochemical Genetic Tests
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Research Laboratories & CROs
• Hospitals & Clinics
• Diagnostic Laboratories
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Disease
  • 1.2.2. Specialty
  • 1.2.3. Technology
  • 1.2.4. End Use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Disease outlook
  • 2.2.2. Specialty outlook
  • 2.2.3. Technology outlook
  • 2.2.4. End Use outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Rare Disease Genetic Testing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Expanding patient registry for rare disease
    • 3.2.1.2. Declining sequencing cost
    • 3.2.1.3. Technological advancements in disease diagnosis
    • 3.2.1.4. Launch of programs & new product development in rare disease diagnosis
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Absence of effective diagnosis framework
    • 3.2.2.2. Technical challenges associated with genetic tests & data management
• 3.3. Rare Disease Genetic Testing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Rare Disease Genetic Testing Market: Disease Estimates & Trend Analysis

• 4.1. Disease Market Share, 2025 & 2033
• 4.2. Segment Dashboard
• 4.3. Global Rare Disease Genetic Testing Market by Disease Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 4.4.1. Neurological Disorders
    • 4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.2. Immunological Disorders
    • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.3. Hematology Diseases
    • 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.4. Endocrine & Metabolism Diseases
    • 4.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.5. Cancer
    • 4.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.6. Musculoskeletal Disorders
    • 4.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.7. Cardiovascular Disorders
    • 4.4.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.8. Dermatology Diseases
    • 4.4.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.9. Other Rare Diseases
    • 4.4.9.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Rare Disease Genetic Testing Market: Technology Estimates & Trend Analysis

• 5.1. Technology Market Share, 2025 & 2033
• 5.2. Segment Dashboard
• 5.3. Global Rare Disease Genetic Testing Market by Technology Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.4.1. Next Generation Sequencing
    • 5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.1.2. Whole Exome Sequencing
      • 5.4.1.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.1.3. Whole Genome Sequencing
      • 5.4.1.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.2. Array Technology
    • 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.3. PCR-based Testing
    • 5.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.4. FISH
    • 5.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.5. Sanger Sequencing
    • 5.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.6. Karyotyping
    • 5.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Rare Disease Genetic Testing Market: Specialty Estimates & Trend Analysis

• 6.1. Specialty Market Share, 2025 & 2033
• 6.2. Segment Dashboard
• 6.3. Global Rare Disease Genetic Testing Market by Specialty Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.4.1. Molecular Genetic Tests
    • 6.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
  • 6.4.2. Biochemical Genetic Tests
    • 6.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.3. Chromosomal Genetic Tests
    • 6.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Rare Disease Genetic Testing Market: End Use Estimates & Trend Analysis

• 7.1. End Use Market Share, 2025 & 2033
• 7.2. Segment Dashboard
• 7.3. Global Rare Disease Genetic Testing Market by End Use Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 7.4.1. Research Laboratories & CROs
    • 7.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
  • 7.4.2. Hospitals & Clinics
    • 7.4.2.1. Market estimates and forecasts 2021 to 2033 (USD million)
  • 7.4.3. Diagnostic Laboratories
    • 7.4.3.1. Market estimates and forecasts 2021 to 2033 (USD million)

Chapter 8. Rare Disease Genetic Testing Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2025 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 8.5. North America
  • 8.5.1. U.S.
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.2. Canada
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.3. Mexico
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Europe
  • 8.6.1. UK
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.2. Germany
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.3. France
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.4. Italy
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/ reimbursement structure
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.5. Spain
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/ reimbursement structure
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.6. Norway
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework/ reimbursement structure
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.7. Sweden
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework/ reimbursement structure
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.8. Denmark
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework/ reimbursement structure
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Japan
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.2. China
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.3. India
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.4. Australia
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.5. South Korea
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/ reimbursement structure
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.6. Thailand
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework/ reimbursement structure
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 8.8. Latin America
  • 8.8.1. Brazil
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework/ reimbursement structure
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.2. Argentina
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework/ reimbursement structure
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 8.9. MEA
  • 8.9.1. South Africa
    • 8.9.1.1. Key country dynamics
    • 8.9.1.2. Regulatory framework/ reimbursement structure
    • 8.9.1.3. Competitive scenario
    • 8.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9.2. Saudi Arabia
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework/ reimbursement structure
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9.3. UAE
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework/ reimbursement structure
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9.4. Kuwait
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework/ reimbursement structure
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company market share analysis, 2025
  • 9.3.4. Quest Diagnostics Inc.
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Disease benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Centogene N.V.
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Disease benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Invitae Corp.
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Disease benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. 3billion, Inc.
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Disease benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Arup Laboratories
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Disease benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Eurofins Scientific
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Disease benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Strand Life Sciences
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Disease benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Ambry Genetics
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Disease benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. Perkin Elmer, Inc.
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Disease benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. Realm IDX, Inc.
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Disease benchmarking
    • 9.3.13.4. Strategic initiatives
  • 9.3.14. Macrogen, Inc.
    • 9.3.14.1. Company overview
    • 9.3.14.2. Financial performance
    • 9.3.14.3. Disease benchmarking
    • 9.3.14.4. Strategic initiatives
  • 9.3.15. Baylor Genetics
    • 9.3.15.1. Company overview
    • 9.3.15.2. Financial performance
    • 9.3.15.3. Disease benchmarking
    • 9.3.15.4. Strategic initiatives
  • 9.3.16. Color Genomics, Inc.
    • 9.3.16.1. Company overview
    • 9.3.16.2. Financial performance
    • 9.3.16.3. Disease benchmarking
    • 9.3.16.4. Strategic initiatives
  • 9.3.17. Health Network Laboratories
    • 9.3.17.1. Company overview
    • 9.3.17.2. Financial performance
    • 9.3.17.3. Disease benchmarking
    • 9.3.17.4. Strategic initiatives
  • 9.3.18. PreventionGenetics
    • 9.3.18.1. Company overview
    • 9.3.18.2. Financial performance
    • 9.3.18.3. Disease benchmarking
    • 9.3.18.4. Strategic initiatives
  • 9.3.19. Progenity, Inc.
    • 9.3.19.1. Company overview
    • 9.3.19.2. Financial performance
    • 9.3.19.3. Disease benchmarking
    • 9.3.19.4. Strategic initiatives
  • 9.3.20. Coopersurgical, Inc.
    • 9.3.20.1. Company overview
    • 9.3.20.2. Financial performance
    • 9.3.20.3. Disease benchmarking
    • 9.3.20.4. Strategic initiatives
  • 9.3.21. Fulgent Genetics Inc.
    • 9.3.21.1. Company overview
    • 9.3.21.2. Financial performance
    • 9.3.21.3. Disease benchmarking
    • 9.3.21.4. Strategic initiatives
  • 9.3.22. Myriad Genetics, Inc.
    • 9.3.22.1. Company overview
    • 9.3.22.2. Financial performance
    • 9.3.22.3. Disease benchmarking
    • 9.3.22.4. Strategic initiatives
  • 9.3.23. Laboratory Corporation of America Holdings
    • 9.3.23.1. Company overview
    • 9.3.23.2. Financial performance
    • 9.3.23.3. Disease benchmarking
    • 9.3.23.4. Strategic initiatives
  • 9.3.24. Opko Health, Inc.
    • 9.3.24.1. Company overview
    • 9.3.24.2. Financial performance
    • 9.3.24.3. Disease benchmarking
    • 9.3.24.4. Strategic initiatives
  • 9.3.25. Artemis DNA
    • 9.3.25.1. Company overview
    • 9.3.25.2. Financial performance
    • 9.3.25.3. Disease benchmarking
    • 9.3.25.4. Strategic initiatives